Abstract. – AIM: Vitamin D deficiency is very common among HIV-infected subjects. We cross-sectionally evaluated the prevalence and risk factors for hypovitaminosis D in 91 HIV-infected Italian patients.

PATIENTS AND METHODS: We studied in a cohort of 91 HIV-infected Italian patients the metabolism of Vitamin D by evaluating the in vitro expression of CYP27B1, CYP24A1 and vitamin D receptor (VDR) by monocytes and macrophages stimulated with the viral envelope protein gp120 or lipopolysaccharide (LPS).

RESULTS: The prevalence of vitamin D deficiency (25OHD < 10 ng/ml) and vitamin D insufficiency (25OHD 10-30 ng/ml) was 31% and 57%, respectively. In univariate analysis, female sex (p = 0.01), increasing age (p = 0.05), higher highly sensitive-C reactive protein (p = 0.025), higher parathyroid hormone (PTH) (p = 0.043) and lower BMI (p = 0.04) were associated with vitamin D deficiency. In multivariate analysis, the association was still significant only for PTH (p = 0.03) and female sex (p = 0.03).

Monocyte stimulation with LPS (100 ng/ml) or gp120 (1 µg/ml) significantly upregulated CYP27B1 mRNA expression. Moreover, gp120 significantly increased VDR mRNA levels. On the contrary, neither LPS nor gp120 modified CYP24A1 levels. Macrophage stimulation with LPS (100 ng/ml) significantly upregulated CYP27B1 and CYP24A1 mRNA expression.

LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals

M.R. PINZONE1, M. DI ROSA1, B.M. CELESIA1, F. CONDORELLI2, M. MALAGUARNERA3, G. MADEDDU4, F. MARTELLOTA5, D. CASTRONUOVO1, M. GUSSIO1, C. COCO1, F. PALERMO1, S. COSENTINO1, B. CACOPARDO1, G. NUNNARI1,6

1Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, Catania, Italy
2DISCAFF & DFB Center, University of Piemonte Orientale A. Avogadro, Novara, Italy
3International PhD programme in Neuropharmacology, University of Catania, Catania, Italy
4Department of Clinical, Experimental and Oncological Medicine, Division of Infectious Diseases, University of Sassari, Sassari, Italy
5Department of Medical Oncology, National Cancer Institute, Aviano Italy
6Department of Microbiology and Immunology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, USA

Corresponding Author: Giuseppe Nunnari, MD, Ph.D, MPH; e-mail: gnunnari@hotmail.com
increased prevalence of metabolic and cardiovascular disease, malignancies, bone and renal disease observed in HIV-infected subjects. In fact, direct or indirect markers of inflammation, such as highly sensitive (hs)-C reactive protein (CRP) and Interleukin (IL)-6, and coagulation, such as D-dimer, and circulating levels of bacterial lipopolysaccharide (LPS), have been associated with increased morbidity and mortality in the setting of HIV.

Vitamin D is involved not only in bone homeostasis, but it also has non-skeletal functions, including immune regulation. Vitamin D deficiency has been associated with increased levels of pro-inflammatory cytokines and increased systemic inflammation.

In recent years a growing number of studies have reported high prevalence rates of vitamin D deficiency among HIV-infected patients. Hypovitaminosis D has a multifactorial origin, including non-HIV-related risk factors, such as female sex, low dietary intake and low sun exposure, and HIV-related factors, i.e. immune activation and antiretroviral adverse effects. Several reports have identified vitamin D deficiency as an independent risk factor not only for osteoporosis and fragility fractures, but also for cardiovascular and metabolic disorders among HIV-positive subjects.

In the present study, we cross-sectionally evaluated the prevalence of vitamin D deficiency in a cohort of HIV-infected subjects and the risk factors associated with hypovitaminosis D, including inflammation and coagulopathic markers. Then, we studied in vitro the expression of CYP27B1 and CYP24A1, the enzymes involved in vitamin D metabolism and catabolism, respectively, and vitamin D receptor (VDR), upon monocyte and macrophage stimulation with LPS or the HIV envelope protein gp120. We also measured vitamin D levels in the supernatant of monocytes stimulated with LPS, LPS plus 25-hydroxyvitamin D (25OHD) or 25OHD alone.

**Patients and Methods**

**Study Population**

From March to May 2011, 91 consecutive HIV-positive patients were enrolled for this study during their regularly scheduled ambulatory care visits at the Unit of Infectious Disease, Garibaldi Nesima Hospital, Catania, Italy. Written informed consent was obtained by all participants at enrolment. The following parameters were extracted from medical records: patient demographics, HCV and/or HBV co-infection, body mass index (BMI) and HIV-related parameters, including time since HIV diagnosis and initiation of HAART, route of infection, CDC stage, HAART regimen. Information on smoking habit was obtained by subject interview. The following biochemical and viro-immunological parameters were measured: serum glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, insulin, creatinine, D-dimer, hs-CRP, parathyroid hormone (PTH), CD4+ and CD8+ T-cell count, HIV RNA (Cobas Amplicor HIV-1 monitor test, minimal detection threshold of 20 copies/ml). 25OHD levels were measured using the DiaSorin radioimmunoassay (Stillwater, MN, USA). The level of detection for 25OHD was < 4 ng/ml. The reference range is 32-100 ng/ml. According to EuroSida indications, 25OHD concentration was defined normal when > 30 ng/ml, insufficient when ranging between 10 and 30 ng/ml, deficient when < 10 ng/ml.

**Cell Cultures**

Human monocytes were isolated from fresh buffy coats of healthy volunteers as described in details elsewhere. Peripheral blood mononuclear cells (PBMCs) were diluted with phosphate-buffered saline (PBS) supplemented with 2.5 mM EDTA and plated at a density of 1 × 10^6 cells/well in 6-well plates (Becton Dickinson, Franklin Lakes, NJ, USA). Monocytes were allowed to attach to the wells for 2 hours (h) at 37°C in 5% CO₂, after which non-adherent cells were removed by washing three times with PBS. Monocytes were cultured in Iscove’s Modified Dulbecco’s Medium supplemented with rHuman Macrophage-Colony Stimulating Factor (M-CSF) 5 ng/ml (PeproTech, BDA, Segrate, Milan, Italy), 10% fetal bovine serum (FBS), 2 mM glutamine and 1% of penicillin/streptomycin (Invitrogen, Milan, Italy). Mature macrophages were obtained from monocytes after 7 days of culture without changing the medium.

To determine the effects of glycoprotein 120 (gp120) on Vitamin D (1,25-dihydroxyvitamin D3) receptor (VDR), CYP24A1, CYP27B1 and IL-6 expression on freshly isolated monocytes, cells were treated immediately after adhesion with gp120 (1 µg/ml, ImmunoDiagnostics, Boston, MA, USA) or left untreated, samples were evaluated at 3h and 24h. Analogously, to evaluate the effects of LPS on VDR, CYP24A1,
CYP27B1 and IL-6 expression, monocytes were treated with LPS (100 ng/ml, Sigma-Aldrich, Milan, Italy) or left untreated and samples collected at different time points (2h, 4h, 8h and 24h). mRNA levels were measured by real-time RT-polymerase chain reaction (PCR). Similarly, macrophages were treated with LPS (100 ng/ml, Sigma-Aldrich, Milan, Italy) and samples evaluated at 2h, 4h and 6h. We also stimulated monocytes with LPS (100 ng/ml) ± 25OHD (40 ng/ml, Sigma-Aldrich, Milan, Italy) or with 25OHD alone for 24h and we measured 25OHD levels in the supernatants.

In another series of experiments, we isolated monocytes from 5 vitamin D-sufficient healthy controls, 5 HIV-positive patients with 25OHD < 10 ng/ml and 5 HIV-positive patients with 25OHD > 10 ng/ml and we evaluated baseline expression of IL-6 mRNA as well as IL-6 levels after monocyte treatment with 1,25-dihydroxyvitamin D (1,25OH₂D) (1 µM, Sigma-Aldrich, Milan, Italy) for 24h.

**Gene Expression Analysis by Real-Time PCR**

Total RNA was extracted from cells using TRIzol reagent (Invitrogen, Milan, Italy). For reverse transcription-PCR (RT-PCR), 2 µg of total RNA were reverse-transcribed with high-capacity cDNA Reverse Transcription Kit (Applied Biosystems, Monza, Italy) in a 20 µl reaction volume. Real-time fluorescence PCR, based on SYBR Green, was carried out in a 30 µl final volume containing 1 µl SYBR Green PCR Master Mix (Applied Biosystems, Monza, Italy), 200 nM forward and 200 nM reverse primers (Table I) and 20 ng of cDNA. Thermal cycling was performed for each gene in triplicate on cDNA samples in MicroAmp Optical 96-well reaction plate (Applied Biosystems, Monza, Italy) with MicroAmp optical caps (Applied Biosystems, Monza, Italy), using the ABI PRISM 7700 sequence detection system (Applied Biosystems, Monza, Italy). Amplification was carried out with the following conditions: 50°C for 2 min, 95°C for 10 min and 40 cycles each of 95°C for 15 s and 60°C for 1 min.

**Statistical Analysis**

Statistical analysis was performed using SPSS statistical software package release 14.0.2 (SPSS Inc., Chicago, IL, USA) and Graphpad Prism 4 software (GraphPad, La Jolla, CA, USA).

Continuous variables are expressed as median (interquartile range, IQR) and compared by non-parametric Mann-Whitney and Kruskal-Wallis test, when appropriate. Categorical variables are presented as number of cases (percentage) and were compared using Fisher’s exact and chi-square test, when appropriate. Correlations between different parameters were analyzed by Spearman’s correlation coefficient. Univariate and multivariate regression analysis were used to identify significant factors associated with 25OHD deficiency. We included in multivariable analysis all variables with a p-value less than 0.2 in univariate analysis.

For in vitro experiments, data are expressed as mean ± standard deviation (SD). Significance was assessed by one-way analysis of variance (ANOVA) and Student’s t-test.

**Results**

**Study Population Characteristics and Vitamin D Levels**

The characteristics of the study population are shown in Table II.

Median age was 45 (40-51) years and 74% were men. 20% of patients had hepatitis C coinfection, 54% were cigarette smokers. 11 patients (12%) were diabetic.

Median time from HIV diagnosis was 155 (62-202) months. Most patients (91.2%) were on HAART. 57% of them were receiving a protease inhibitor (PI)-based regimen, 26% an efavirenz (EFV)-containing regimen, 59% were receiving...

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
<th>Size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>CTGCACCAACTGCTTAG</td>
<td>AGGTCCACCACCTGACAGTT</td>
<td>262</td>
</tr>
<tr>
<td>IL-6</td>
<td>GAAAGCAGCAAAAGAAGCCT</td>
<td>TTTCAACCGGAACTCTCCC</td>
<td>108</td>
</tr>
<tr>
<td>VDR</td>
<td>TCCCTCTGTCAGATCCTG</td>
<td>AGGTCACAGAAGGGTCATC</td>
<td>107</td>
</tr>
<tr>
<td>CYP27B1</td>
<td>TTGCTATTTGCGGCGGAGTGG</td>
<td>TGCCGGGAGAGGTCATCAG</td>
<td>68</td>
</tr>
<tr>
<td>CYP24A1</td>
<td>ATGAGCACGTTTGCGAGGAT</td>
<td>TGCCAGACCTTGGTGTGAG</td>
<td>70</td>
</tr>
</tbody>
</table>
LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1.

tenofovir (TDF). Median CD4+ T-cell count was 538 (389-766) cells/µl and 63% of patients had an undetectable viral load (<20 copies/ml).

Median 25OHD concentration was 17 (9.15-24.1) ng/ml. In our population, only 12% of subjects had 25OHD levels above 30 ng/ml. Most of them (57%) were 25OHD insufficient, whereas the prevalence rate of 25OHD deficiency was 31%. Median hs-CRP level was 0.17 (0.08-0.87) mg/dl. Median PTH level was 49.6 (39.1-60.3) pg/ml, median insulin level was 8.8 (5.17-11.4) microu/ml. Median D-Dimer level was 164.5 (119.3-226.8) ng/ml.

Factors Associated with Vitamin D Deficiency

Table III summarizes factors associated with vitamin D deficiency in our cohort of patients.

In univariate analysis, vitamin D deficiency was found to correlate with age and female sex (Figure 1), as patients with 25OHD < 10 ng/ml were significantly older than those with 25OHD > 10 ng/ml (48 vs. 45 years, \( p = 0.05 \); \( r = –0.26, p = 0.01 \)). Similarly, women were more represented in the vitamin D-deficient group (42.8 vs. 17.4%, \( p = 0.01 \)). Vitamin D-deficient patients had lower BMI (22.2 vs. 24 kg/m², \( p = 0.04 ; r = 0.2 \), \( p = 0.15 \)) and higher PTH (63 vs. 47 pg/ml, \( p = 0.043 ; r = –0.21, p = 0.05 \)) in comparison with subjects having 25OHD > 10 ng/ml. In addition, hs-CRP levels were significantly higher among vitamin D-deficient patients (0.32 vs. 0.19 mg/dl, \( p = 0.025; r = –0.23, p = 0.033 \)) (Figure 1).

CD4+ and CD8+ T-cell count, viral load, time since HIV diagnosis, CDC stage and route of infection did not significantly differ between groups. HCV coinfection and diabetes did not affect vitamin D status. Analogously, we did not find any significant correlation between HAART and vitamin D levels, as well as between any antiretroviral class and 25OHD serum concentra-

### Table II. Characteristics of our study population.

<table>
<thead>
<tr>
<th>Patients' characteristics</th>
<th>N = 91</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (IQR)</td>
<td>45 (40-51)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>67 (73.6)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>24 (26.4)</td>
</tr>
<tr>
<td>CDC stage A, n (%)</td>
<td>55 (60.4)</td>
</tr>
<tr>
<td>CDC stage B, n (%)</td>
<td>14 (15.4)</td>
</tr>
<tr>
<td>CDC stage C, n (%)</td>
<td>22 (24.2)</td>
</tr>
<tr>
<td>Risk</td>
<td></td>
</tr>
<tr>
<td>Omosexual, n (%)</td>
<td>37 (40.6)</td>
</tr>
<tr>
<td>Eterosexual, n (%)</td>
<td>36 (39.6)</td>
</tr>
<tr>
<td>Intravenous drug use, n (%)</td>
<td>11 (12.1)</td>
</tr>
<tr>
<td>Other, n (%)</td>
<td>7 (7.7)</td>
</tr>
<tr>
<td>Hepatitis C coinfection, n (%)</td>
<td>18 (19.8)</td>
</tr>
<tr>
<td>Active smokers, n (%)</td>
<td>49 (53.8)</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>11 (12)</td>
</tr>
<tr>
<td>Body mass index (kg/m²), median (IQR)</td>
<td>23.9 (22-26.2)</td>
</tr>
<tr>
<td>Glomerular filtration rate (ml/min), median (IQR)</td>
<td>111 (90.7-134.6)</td>
</tr>
<tr>
<td>Current HAART, n (%)</td>
<td>83 (91.2)</td>
</tr>
<tr>
<td>Time since HIV diagnosis (months), median (IQR)</td>
<td>155 (62-202)</td>
</tr>
<tr>
<td>Time spent on HAART (months), median (IQR)</td>
<td>121 (25-171)</td>
</tr>
<tr>
<td>Current exposure to efavirenz, n (%)</td>
<td>24 (26.4)</td>
</tr>
<tr>
<td>Current exposure to protease inhibitors, n (%)</td>
<td>52 (57.1)</td>
</tr>
<tr>
<td>Current exposure to tenofovir, n (%)</td>
<td>54 (59.3)</td>
</tr>
<tr>
<td>Current CD4+ T-cell count (cells/µl), median (IQR)</td>
<td>538 (389-766)</td>
</tr>
<tr>
<td>HIV RNA &lt; 20 copies/ml, n (%)</td>
<td>57 (62.6)</td>
</tr>
<tr>
<td>25OHD &lt; 10 ng/ml, median (IQR)</td>
<td>17 (9.15-24.1)</td>
</tr>
<tr>
<td>25OHD 10-30 ng/ml, n (%)</td>
<td>28 (30.8)</td>
</tr>
<tr>
<td>25OHD &gt; 30 ng/ml, n (%)</td>
<td>52 (57.1)</td>
</tr>
<tr>
<td>Parathyroid hormone (pg/ml), median (IQR)</td>
<td>49.6 (39.1-60.3)</td>
</tr>
<tr>
<td>Insulin (microU/ml), median (IQR)</td>
<td>8.8 (5.17-11.4)</td>
</tr>
<tr>
<td>D-Dimer (ng/ml), median (IQR)</td>
<td>164.5 (119.3-226.8)</td>
</tr>
<tr>
<td>Highly sensitive-C reactive protein (mg/dl), median (IQR)</td>
<td>0.17 (0.08-0.87)</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl), median (IQR)</td>
<td>195 (160-220)</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dl), median (IQR)</td>
<td>37 (31-43)</td>
</tr>
</tbody>
</table>

### Table III. Factors associated with vitamin D deficiency in our study population.

<table>
<thead>
<tr>
<th>Patients' characteristics</th>
<th>25OHD &lt; 10 ng/ml</th>
<th>25OHD &gt; 10 ng/ml</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (IQR)</td>
<td>48 (42-57)</td>
<td>45 (38-49)</td>
<td>( p = 0.05 )</td>
<td>( p = 0.4 )</td>
</tr>
<tr>
<td>Sex: Female, n (%)</td>
<td>12 (42.8)</td>
<td>11 (37.4)</td>
<td>( p = 0.01 )</td>
<td>( p = 0.03 )</td>
</tr>
<tr>
<td>Body mass index (kg/m²), median (IQR)</td>
<td>22.2 (19.2-25.5)</td>
<td>24 (22.2-27.2)</td>
<td>( p = 0.04 )</td>
<td>( p = 0.24 )</td>
</tr>
<tr>
<td>Glomerular filtration rate (ml/min), median (IQR)</td>
<td>104 (81-114)</td>
<td>116 (96-143)</td>
<td>( p = 0.13 )</td>
<td>( p = 0.77 )</td>
</tr>
<tr>
<td>Parathyroid hormone (pg/ml), median (IQR)</td>
<td>62.6 (39.1-109)</td>
<td>47.1 (33.4-57.8)</td>
<td>( p = 0.043 )</td>
<td>( p = 0.03 )</td>
</tr>
<tr>
<td>Highly sensitive-C reactive protein (mg/dl), median (IQR)</td>
<td>0.32 (0.08-0.88)</td>
<td>0.19 (0.09-0.33)</td>
<td>( p = 0.025 )</td>
<td>( p = 0.07 )</td>
</tr>
<tr>
<td>Time spent on HAART (months), median (IQR)</td>
<td>163 (66-177)</td>
<td>132 (26-176)</td>
<td>( p = 0.19 )</td>
<td>( p = 0.65 )</td>
</tr>
</tbody>
</table>
tion. Insulin, D-dimer and cholesterol levels were similar among patients who were vitamin D-deficient and patients who were not.

In a logistic regression model (Table III), only PTH ($p = 0.03$) and female sex ($p = 0.03$) were still associated with vitamin D deficiency.

In vitro Experiments

Effects of HIV gp120 on VDR, CYP24A1, CYP27B1 and IL-6 Expression in Human Monocytes

As shown in Figure 2, monocyte treatment with gp120 significantly increased CYP27B1 mRNA expression (356.7%, $p < 0.05$) compared with the control group, as well as VDR (174.11%, $p < 0.05$). As for CYP24A1, we noticed a slight, not significant increase in the expression at 3h.

Effects of LPS on VDR, CYP24A1, CYP27B1 and IL-6 Expression in Human Monocytes

We examined the effect of LPS on VDR, CYP24A1, CYP27B1 and IL-6 expression on freshly isolated monocytes. As shown in Figure 3, monocyte treatment with LPS significantly increased CYP27B1 mRNA expression, with the highest stimulation at 24h (258%, $p < 0.05$). CYP24A1 and VDR expression were not significantly affected by treatment with LPS. As for IL-6, its levels significantly increased at 4h (134%, $p < 0.05$) and then decreased over time (75%, $p < 0.05$).

Effects of LPS on VDR, CYP24A1, CYP27B1 and IL-6 Expression in Human Macrophages

We examined the effect of LPS on VDR, CYP24A1, CYP27B1 and IL-6 expression on macrophages. As shown in Figure 4, macrophage treatment with LPS significantly increased CYP27B1 mRNA expression, with the highest stimulation at 6h (23-fold increase, $p < 0.01$). CYP24A1 mRNA expression was significantly up-regulated at 2h (18-fold increase, $p < 0.01$) and 4h (12-fold increase, $p < 0.01$). VDR expression was not significantly affected by treatment with LPS. As for IL-6, its levels significantly increased upon LPS stimulation, with the highest expression at 6h (22-fold increase, $p < 0.01$).

In vitro Effects of LPS on Vitamin D Consumption

As shown in Figure 5, we found that vitamin D levels were significantly lower in the super-
Figure 2. Quantification of CYP27B1, CYP24A1, vitamin D receptor (VDR) and Interleukin (IL)-6 mRNA expression by real-time polymerase chain reaction in human monocytes, at 3h and 24h, following treatment with gp120 (1 µg/ml). Expression levels are calculated as $\Delta \Delta Ct$ value. Data are representative of three independent experiments. *$p < 0.05$ in comparison with control (CTRL).

Figure 3. Quantification of CYP27B1, CYP24A1, vitamin D receptor (VDR) and Interleukin (IL)-6 expression by real-time polymerase chain reaction in human monocytes, following treatment with lipopolysaccharide (LPS) (100 ng/ml) at different time points. Expression levels are calculated as $\Delta \Delta Ct$ value. Data are representative of three independent experiments. *$p < 0.05$ in comparison with control (CTRL).
Figure 4. Quantification of CYP27B1, CYP24A1, vitamin D receptor (VDR) and Interleukin (IL)-6 expression by real-time polymerase chain reaction in human macrophages, following treatment with lipopolysaccharide (LPS) (100 ng/ml) at different time points. Expression levels are calculated as ΔDCt value. Data are representative of three independent experiments. *p < 0.01 in comparison with control (CTR).

Figure 5. Evaluation of 25-hydroxyvitamin D (25OHD) levels in the supernatant of monocytes stimulated for 24h with lipopolysaccharide (LPS) (100 ng/ml) ± 25OHD (40 ng/ml), 25OHD (40 ng/ml) and controls. Data are representative of three independent experiments. *p < 0.01.
natant of monocytes treated with LPS plus 25OHD in comparison with monocytes treated with 25OHD alone (75%, p < 0.01). Vitamin D levels in the supernatant of controls and LPS-treated monocytes were unremarkable.

IL-6 mRNA Expression in Monocytes of Healthy Controls and HIV-positive Patients Stimulated with 1,25OH2D

We found no baseline expression of IL-6 mRNA in monocytes of healthy controls. On the contrary, 3 out of 5 (60%) of monocytes isolated from vitamin D-deficient HIV-infected patients and 1 out of 5 (20%) of monocytes from patients with 25OHD > 10 ng/ml patients expressed IL-6 mRNA at baseline. IL-6 levels were higher in monocytes from vitamin D-deficient subjects (p < 0.05). Treatment with 1,25OH2D for 24h significantly reduced IL-6 expression in both groups (74% and 48% respectively, p < 0.01 in comparison with baseline values) (Figure 6).

Discussion

In our cross-sectional study, we evaluated the prevalence of vitamin D deficiency during spring months in a cohort of HIV-positive subjects. Almost 90% of patients had vitamin D levels below 30 ng/ml and about one-third had severe vitamin D deficiency. Similar prevalence rates have been described in several large HIV cohorts: in the SUN study36, 71% of HIV-positive subjects had 25OHD levels below 30 ng/ml, in the EuroSIDA study only 11% of patients had 25OHD levels above 30 ng/ml37. However, vitamin D deficiency seems to be very common even among HIV-negative subjects. In fact, in the SUN study no difference in the prevalence of hypovitaminosis D were found between HIV-positive and HIV-negative subjects36; analogously, Stein et al42 described similar prevalence rates of vitamin D deficiency/insufficiency (about 75%) in both HIV-positive and HIV-negative postmenopausal women.

We observed a significant association between vitamin D deficiency and some established predictors of 25OHD levels, such as age37,38 and female sex46. On the contrary, there was no association between exposure to HAART and 25OHD levels. In fact, even though vitamin D-deficient subjects were on HAART for longer time (163 vs. 132 months), the difference was not statistically significant, possibly because of the small sample size.

Several antiretroviral drugs are known to interfere, at least in vitro, with vitamin D metabo-

Figure 6. Quantification of Interleukin (IL)-6 expression by real-time polymerase chain reaction in human monocytes of healthy controls, HIV-infected patients with 25-hydroxyvitamin D (25OHD) < 10 ng/ml and patients with 25OHD > 10 ng/ml at baseline and after treatment with 1,25-dihydroxyvitamin D (1,25OH2D) (1 µM) for 24h. Expression levels are calculated as ΔDCt value. **p < 0.05; *p < 0.01.
lism. PI have been shown to inhibit vitamin D 1α- and 25α-hydroxylation in hepatocyte and monocyte cultures49, EFV has been associated with increased 25OHD catabolism, through the induction of CYP24A150. Some in vivo studies50-52 have related the administration of EFV with an increased risk of developing vitamin D deficiency. In the present report, we failed to detect any association between 25OHD levels and specific antiretroviral drugs.

Even though some defect in PTH production/secretion in HIV-infected patients has been hypothesized53, we found that patients with 25OHD < 10 ng/ml had significantly higher PTH levels than those with 25OHD > 10 ng/ml. This observation is in keeping with the physiological regulation of PTH-vitamin D-calcium axis, as low vitamin D levels usually result in secondary hyperparathyroidism. Childs et al54 have reported higher PTH levels among patients receiving TDF who were vitamin D-deficient; similar results have been reported by Labarga et al55.

In contrast with other studies, describing obesity as a risk factor for vitamin D deficiency36,56, we found that patients with 25OHD < 10 ng/ml had lower BMI in comparison with those with 25OHD > 10 ng/ml. In a work of Mehta et al57, the Authors reported low 25OHD to correlate with increased risk of wasting, defined as BMI < 18 kg/m2. Increased secretion of pro-inflammatory cytokines, such as tumor necrosis factor-α, IL-1 and IL-6 has been shown to contribute to wasting58-59. Considering the immunomodulatory properties of vitamin D, it can be supposed that vitamin D deficiency may be associated with higher levels of pro-inflammatory cytokines, hence, with an increased risk of wasting. However, even though this mechanism may partially explain the differences in BMI observed in our cohort, this association should be interpreted with caution as almost all patients in our study had BMI within the normal range.

There is a growing evidence relating vitamin D deficiency with inflammation. The present study suggests a positive correlation between hypovitaminosis D and hs-CRP levels. These findings are consistent with a recent report of Palmer et al60, in which participants with 25OHD levels < 20 ng/ml had a 3.2-fold higher odds of high CRP compared to those with a 25OHD serum level ≥ 20 ng/ml. Similarly, in a work of Piroth et al61, vitamin D deficiency correlated with IL-6 and hs-CRP levels, albeit the latter did not reach statistical significance. Given the cross-sectional design of both studies, we could not establish if it is chronic inflammation to contribute to vitamin D deficiency or if it is vitamin D deficiency to increase production of pro-inflammatory cytokines.

It is well known that vitamin D has several immunomodulatory functions, related with both innate and adaptive immunity31,32. In our in vitro experiments, we found that monocytes from vitamin D-deficient subjects expressed IL-6 mRNA in a significantly higher number of cases in comparison with patients with 25OHD > 10 ng/ml, whereas healthy controls did not express IL-6 mRNA. Moreover, treatment with 1,25OHD, D was able to reduce IL-6 levels when added to monocyte cultures in both groups. Monocyte stimulation with both gp120 and LPS upregulated the expression of CYP27B1, the enzyme catalyzing the conversion of 25OHD to 1,25OHD, D, the biologically active metabolite of 25OHD. This mechanism, which can be amplified by residual chronic inflammation, may theoretically reduce circulating 25OHD levels by enhancing its conversion to 1,25OHD, D. Moreover, we found increased CYP24A1 expression in macrophages but not monocytes after LPS stimulation, leading to an increased activation of the catabolic pathway. We also found lower 25OHD levels in the supernatant of monocytes treated with LPS plus 25OHD in comparison with monocytes treated with 25OHD alone. Our in vitro data are in keeping with the findings of Liu et al62, showing increased expression of CYP27B1 in activated macrophages, as well as with the study of Mathieu et al63, describing CYP27B1 upregulation in response to LPS-mediated TLR4/CD14 stimulation. In a recent work of Safdar et al64, higher 1,25OHD,D levels correlated with higher HIV viral load. The Authors suggested immune activation as a possible explanation, as increasing viremia may lead to systemic chronic activation of the immune system, including monocytes/macrophages, which may in turn result in increased conversion of 25OHD to 1,25OHD,D. Although we did not find any significant association between viral load and 25OHD levels, the observation that gp120 upregulates CYP27B1 expression is consistent with this hypothesis. It may be speculated that immune cells, such as monocyte/macrophages and T cells, may convert and utilize 25OHD and 1,25OHD,D to regulate immune responses. This process could ultimately lead to vitamin D consumption and not to a release of 1,25OHD,D in the circulation, which is, instead, what kidney cells do.
Hypovitaminosis D was highly prevalent in our population of HIV-infected subjects. As suggested by current European AIDS Clinical Society guidelines\(^7\), HIV-positive patients should be routinely screened for vitamin D deficiency, in order to identify those requiring supplementation. There is a need for large prospective studies, in order to identify the causal relationship between risk factors and vitamin D deficiency and to extensively study the impact of vitamin D supplementation on immune activation and prevention of comorbidities, also in cancer patients with HIV infection\(^8\).\(^9\).

**Conflict of Interest**

No conflict of interest to declare. The present study was supported by internal funds of the University of Catania, Italy. These data were presented in part at the SIMIT Conference, La Maddalena, Italy 2011 and at the International AIDS Conference, Washington D.C., USA 2012.

**References**


LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1


GERUNDA G. Don’t deny Liver transplantation to HIV-positive patients with HCC in the HAART-era. JCO 2006; 24: e26-27.


